Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct 13:10:3355-3361.
doi: 10.2147/DDDT.S85050. eCollection 2016.

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

Dilek Keskin  1 , Sevil Sadri  1 , Ahmet Emre Eskazan  1
Affiliations
Review

Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations

Dilek Keskin et al. Drug Des Devel Ther. .

Abstract

Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. It is also utilized in Philadelphia chromosome-positive acute lymphocytic leukemia. While choosing the appropriate tyrosine kinase inhibitor (ie, dasatinib) for each individual patient, comorbidities and BCR-ABL1 kinase domain mutations should always be taken into consideration, among other things. This review mainly focuses on patient selection prior to dasatinib administration in the treatment of chronic myeloid leukemia.

Keywords: chronic myeloid leukemia; comorbidity; dasatinib; mutation; tyrosine kinase inhibitor.

PubMed Disclaimer

Conflict of interest statement

AEE had received honorarium from Novartis. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gugliotta G, Castagnetti F, Apolinari M, et al. First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies. Drugs. 2014;74(6):627–643. - PubMed
    1. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89(5):547–556. - PubMed
    1. Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther. 2015;9:773–779. - PMC - PubMed
    1. Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia. 2011;25(1):7–22. - PubMed
    1. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. - PMC - PubMed

MeSH terms